Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis

Summary

Part 1: To investigate the safety and tolerability of intravenous (IV) or subcutaneous (SC) administration of a single dose of KHK4323 to Japanese or Caucasian healthy adult males in a double-blind, placebo-controlled study. Part 2: To investigate the safety and tolerability of intravenous (IV) administration of repeated doses of KHK4323 to atopic dermatitis patients in a double-blind, placebo-controlled study.

Timeline

Start

2019-02-22

Primary completion

2019-12-11

Completion

2019-12-11

Outcome

Outcome not reported

Stopped: “The study terminated for safety reasons.”

Drugs

Indications